Table of Contents
- Large Study Finds No Evidence Cannabis Use Accelerates Cognitive Decline or Dementia Risk in Older Adults
Large Study Finds No Evidence Cannabis Use Accelerates Cognitive Decline or Dementia Risk in Older Adults
Two major cohorts totaling nearly 300,000 participants and complementary Mendelian randomisation analyses converge on a null finding for cannabis and cognitive aging, though unmeasured exposure details including dose, frequency, and product potency leave important clinical questions unanswered.
Why This Matters
Cannabis use among older adults has increased sharply over the past decade, driven by expanding legalization and growing interest in cannabinoids for pain, sleep, and anxiety. Yet clinicians have had remarkably little large-scale evidence to guide conversations about whether cannabis use poses risks to cognitive health in aging populations. With dementia already among the leading causes of disability worldwide, any modifiable contributor to cognitive decline demands rigorous investigation. This study arrives at a moment when the gap between clinical access and clinical evidence has never been wider.
Clinical Summary
Cannabis exposure in older adults has been studied primarily in small cross-sectional samples, leaving the field without robust longitudinal or causal data. This original observational cohort study, published in Addiction in 2025, addresses that gap by combining repeated cognitive assessments from the UK Biobank (UKB) with incident dementia outcomes from the Million Veteran Program (MVP), then triangulating findings through two-sample Mendelian randomisation. The mechanistic concern motivating this work centers on the endocannabinoid system’s role in hippocampal synaptic plasticity, neuroinflammation, and amyloid processing, all pathways implicated in age-related cognitive decline and neurodegeneration.
Across up to 79,573 UKB participants, lifetime cannabis users showed modestly higher baseline scores on numeric memory (beta = 0.12, 95% CI 0.10 to 0.13 for fluid intelligence), but no significant differences emerged in longitudinal cognitive trajectories across any of five domains tested. In the MVP cohort of 222,518 veterans, cannabis use disorder was not significantly associated with incident all-cause dementia (HR = 1.11, 95% CI 0.97 to 1.26, p = 0.12), though the upper bound does not exclude a clinically meaningful 26% elevated hazard. Mendelian randomisation analyses found no evidence of a bidirectional causal relationship. The authors acknowledge that neither cohort captured dose, frequency, duration, or THC-to-CBD composition of cannabis use, and they emphasize that the findings cannot address whether heavy or high-potency use in older adults carries cognitive risk. Prospective studies with granular exposure measurement are needed before these results can translate into definitive clinical guidance.
Dr. Caplan’s Take
This study does something valuable: it offers the largest observational dataset we have on cannabis and cognitive aging, and it wisely triangulates with Mendelian randomisation to strengthen causal inference. The null finding is genuinely reassuring for the patient sitting in front of me who has used cannabis occasionally and worries about dementia. But there is a significant gap between “lifetime ever-use in a UK population cohort” and the clinical reality of a 68-year-old using high-THC products nightly for chronic pain. The exposure measurement here simply cannot speak to that scenario.
In practice, when patients ask me whether cannabis will affect their memory long-term, I use studies like this to provide honest reassurance that occasional or past use does not appear to carry measurable cognitive risk. At the same time, I am transparent that we lack data on the heavy, daily, or high-potency use patterns I see frequently in my clinic. I counsel moderation, favor lower-THC formulations when cannabis is clinically appropriate, and monitor cognition longitudinally in older patients who use cannabis regularly. That is the most defensible position the current evidence supports.
Clinical Perspective
This study sits at a meaningful inflection point in the cannabis-cognition literature. Prior work has been limited by small sample sizes, cross-sectional designs, and younger populations. The current investigation extends the evidence base considerably by demonstrating no significant longitudinal cognitive decline associated with cannabis use in a large, older cohort and no significant dementia risk elevation in a veteran population with clinically diagnosed cannabis use disorder. The Mendelian randomisation component adds an important layer of causal inference that purely observational analyses cannot provide. However, the baseline cognitive advantage seen in cannabis users almost certainly reflects residual confounding from education, socioeconomic status, and health behaviors rather than any neuroprotective effect, and clinicians should not interpret it as evidence of cognitive benefit.
From a pharmacological standpoint, clinicians should remain attentive to the fact that THC acts as a partial agonist at CB1 receptors concentrated in the hippocampus and prefrontal cortex, regions central to memory and executive function. The absence of harm signal in this study does not eliminate the biological plausibility of dose-dependent effects, particularly with high-potency products. Drug interactions with anticholinergics, benzodiazepines, and other CNS depressants commonly prescribed in older adults also warrant vigilance. The single most actionable recommendation for clinicians today is to document cannabis use in older patients with the same rigor applied to alcohol and tobacco, including product type, frequency, and potency, so that emerging evidence can be meaningfully applied at the individual patient level.
Study at a Glance
What Kind of Evidence Is This
This is an original observational cohort study that combines cross-sectional and longitudinal cognitive analyses from one cohort with Cox proportional hazards modeling of incident dementia from another, supplemented by two-sample Mendelian randomisation for causal inference. Observational cohort studies sit in the middle tier of the evidence hierarchy: they can identify associations in large populations but cannot establish causation on their own. The Mendelian randomisation component strengthens causal inference through genetic triangulation but depends on assumptions, including the absence of horizontal pleiotropy, that cannot be fully verified. The single most important inference constraint is that crude exposure measurement in both cohorts prevents any conclusions about dose-response relationships.
How This Fits With the Broader Literature
Prior studies examining cannabis and cognition in older adults have been limited by small samples, short follow-up periods, and cross-sectional designs that cannot distinguish cause from consequence. A 2024 systematic review of cannabis and cognitive aging noted the absence of large longitudinal investigations as a critical gap. This study directly addresses that gap and aligns with earlier Mendelian randomisation analyses by Pasman et al. (2018) that found no robust causal link between cannabis use and cognitive outcomes in younger populations. The extension to dementia endpoints and an older demographic is novel.
However, this study’s findings should not be read as contradicting evidence from neuroimaging and acute dosing studies showing that heavy THC exposure can impair hippocampal function. Those studies typically examine active, frequent users consuming high-potency products, a population poorly represented by UKB’s lifetime ever-use variable. The current findings are best understood as evidence that population-level cannabis exposure, as crudely measured in these cohorts, does not detectably accelerate cognitive aging.
Common Misreadings
The most likely overinterpretation is that this study demonstrates cannabis is safe for the aging brain. It does not. The exposure measures are too coarse to address the scenarios of greatest clinical concern: daily or near-daily use of high-THC products over years. A single lifetime ever-use question and an ICD-coded disorder diagnosis capture opposite extremes of the use spectrum while missing the broad middle ground where most older adult cannabis users actually fall. Equally problematic would be interpreting the modestly higher baseline cognitive scores among cannabis users as evidence of neuroprotection. The authors themselves attribute this finding to residual confounding, and no longitudinal benefit was observed. Finally, the dementia hazard ratio of 1.11 should not be dismissed as definitively null; the confidence interval extends to 1.26, which is compatible with a clinically meaningful elevation in risk that this study was insufficiently powered or followed for too briefly to detect.
Bottom Line
This large two-cohort study with Mendelian randomisation triangulation provides the most robust evidence to date that cannabis use, as crudely measured by lifetime ever-use or clinical disorder diagnosis, is not significantly associated with accelerated cognitive decline or dementia risk in older adults. It does not establish that heavy, frequent, or high-potency cannabis use is cognitively safe. Clinicians can offer measured reassurance to patients with past or occasional use while emphasizing that the question of dose-dependent harm remains unanswered.
Frequently Asked Questions
Does this study prove that cannabis protects memory or brain health?
No. While cannabis users in one cohort showed slightly higher baseline cognitive scores, the researchers attribute this to confounding factors such as education and lifestyle rather than to any protective effect of cannabis itself. No cognitive benefit was observed over time, and the Mendelian randomisation analysis found no causal evidence of neuroprotection.
I use cannabis daily for chronic pain. Does this study apply to me?
Only partially. The UK Biobank cohort defined cannabis exposure as having ever used the substance in a lifetime, which groups occasional past users with frequent current users. The study cannot distinguish between these patterns and did not measure how much, how often, or what type of cannabis people consumed. If you are a daily user of high-THC products, the study’s reassuring findings may not fully apply to your situation.
Should I stop using cannabis because of dementia concerns?
This study does not provide a reason to stop cannabis use solely based on dementia risk. The hazard ratio for dementia among those with cannabis use disorder was not statistically significant, though it was not definit
